Results 211 to 220 of about 197,879 (225)

Plastic recycling: Challenges and opportunities

The Canadian Journal of Chemical Engineering, EarlyView.
Abstract This review offers an in‐depth exploration of current strategies for recycling plastic waste, focusing on mechanical, chemical, and energy recovery methods. It situates these strategies within the context of modern practices by examining ongoing research methodologies and specific case studies related to various types of plastic waste.
Pradeep Sambyal, Parisa Najmi, Devansh Sharma, Ehsan Khoshbakhti, Hadi Hosseini, Abbas S. Milani, Mohammad Arjmand   +6 more
wiley   +1 more source

Efficacy of Aflibercept (8 mg) for Diabetic Macular Edema in Vitrectomized Eyes Refractory to the Other Anti-VEGF Drug Therapies: A Report of Three Cases. [PDF]

Int Med Case Rep J
Kashiwagi I, Nonaka R, Sasaki S, Yamamoto T, Yasuda K, Shimura M.   +5 more
europepmc   +1 more source

Study on the effect of co‐plasticization of post‐industrial starch for high‐impact thermoplastic starch development

The Canadian Journal of Chemical Engineering, EarlyView.
High‐impact thermoplastic starch blends through the co‐plasticization methodology. Abstract This study analyzed the effect of employing plasticized or co‐plasticized post‐industrial starch in developing PBAT‐based thermoplastic starch (TPS) blends. In this work, the post‐industrial wheat starch was co‐plasticized with glycerol‐urea, glycerol‐citric ...
Aarsha Surendren, Amar K. Mohanty, Loong‐Tak Lim, Qiang Liu, Bassim Abbassi, Manjusri Misra   +5 more
wiley   +1 more source

Underappreciated layers of antibody-mediated immune synapse architecture and dynamics. [PDF]

mBio
Goldberg BS, Ackerman ME.
europepmc   +1 more source

Small‐Molecule KRAS Inhibitors by Tyrosine Covalent Bond Formation

ChemMedChem, Accepted Article.
The development of the KRAS G12C inhibitor sotorasib was a major advance towards drugging KRAS. However, the G12C mutation is only found in about 10% of tumors with a KRAS mutation. KRAS tyrosine amino acids could provide alternative sites for covalent drug development.
Alexander Landgraf, Robert Brenner, Mona Ghozayel, Khuchtumur Bum-Erdene, Giovanni Gonzalez-Gutierrez, Samy Meroueh   +5 more
wiley   +1 more source

Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis. [PDF]

Rheumatology (Oxford)
Smolen JS, Taylor PC, Tanaka Y, Takeuchi T, Hashimoto M, Cara C, Lauwerys B, Tilt N, Ufuktepe B, Xavier RM, Balsa A, Curtis JR, Mikuls TR, Weinblatt M.   +13 more
europepmc   +1 more source

Efanesoctocog alfa: the renaissance of Factor VIII replacement therapy.

Haematologica
Dargaud Y, Leuci A, Ruiz AR, Lacroix-Desmazes S.   +3 more
europepmc   +1 more source

Development of highly bioactive long-acting recombinant porcine FSH for batch production management of sows. [PDF]

Sci Rep
Zhang J, Shi L, Zhong X, Bai Y, Dou J, Zhang L, Shi X, Wu B, Tan Z, Yan L, Yu J, Zhang J, Han G, Xiong J, Zhang H, Cao X, Luo H.   +16 more
europepmc   +1 more source

Bispecific T-cell engagers for the recruitment of T cells in solid tumors: a literature review. [PDF]

Immunother Adv
Dewaele L, Fernandes RA.
europepmc   +1 more source